한글목차

위마비 치료제 동향 및 전망

세계 위마비 치료제 시장은 당뇨병성 위마비, 특발성 위마비, 수술 후 위마비 시장에서의 기회로 인해 미래가 유망할 것으로 예상됩니다. 세계 위마비 치료제 시장은 2024년부터 2030년까지 연평균 4.5%의 성장률을 보일 것으로 예상됩니다. 이 시장의 주요 촉진요인은 수술 건수 증가, 당뇨병 인구의 유병률 증가, 메스꺼움과 구토와 같은 증상을 관리하기 위해 고안된 혁신적인 약물의 출시입니다.

• Lucintel은 약물 유형별로는 구토억제제가 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상하고 있습니다.
• 질병 유형별로는 특발성 위마비가 여전히 가장 큰 부문입니다.
• 지역별로 보면, 고령화 인구의 급격한 증가와 수술 건수 증가로 인해 북미가 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상됩니다.

위마비 치료제 시장의 전략적 성장 기회

이 시장의 주요 전략적 기회에는 다음과 같은 것들이 있습니다.

• 신약 개발에 대한 투자: 신약 개발에 대한 투자: 위마비의 다양한 메커니즘을 표적으로 하는 신약의 창출은 상당한 성장률을 가져올 수 있습니다. 미충족 수요를 충족하고 더 나은 치료법을 제공하기 위해서는 약물 설계와 작용기전에 혁신을 집중해야 합니다.
• 신흥 시장 진출: 더 많은 사람들이 위마비 진단을 받고 위마비에 대한 인식이 높아지는 신흥 시장에서 더 많은 위마비 치료제를 제공함으로써 큰 성장 잠재력이 있습니다. 지역 취향에 맞게 치료제를 현지화함으로써 더 넓은 시장 기회를 확보할 수 있습니다.
• 디지털 헬스 기술 통합: 제약회사와 모바일 헬스 기업의 제휴는 위마비 환자의 예후를 개선하기 위한 복합 모니터링 플랫폼을 개발하는 데 도움이 되고 있습니다. 이러한 통합은 약물 순응도를 향상시키는 동시에 디지털 플랫폼을 통해 임상의에게 개인화된 치료법을 처방할 때 중요한 데이터를 제공합니다.
• 병용요법 개발: 기존 치료와 새로운 약물 및 비약리학적 개입을 통합하는 병용요법에 중점을 두어 위마비를 종합적으로 관리할 수 있습니다. 이러한 접근법은 다양한 증상에 대응하고 전반적인 치료 효과를 향상시킬 수 있습니다.
• 개인화된 의료 접근법: 유전자 프로파일링과 맞춤형 치료를 포함한 개인화된 의료 전략에 투자함으로써 개별 환자에 대한 치료를 최적화할 수 있습니다. 개인화된 접근 방식은 더 나은 치료 결과를 가져오고 시장에서 제품을 차별화할 수 있습니다.

결론적으로, 이러한 전략적 성장 기회는 위마비 치료제 산업에서 혁신과 시장 확대의 잠재력을 강조하고 있습니다. 새로운 기술과 접근 방식을 활용하면 미래 성장을 가속하고 환자 치료를 개선할 수 있습니다.

위마비 치료제 시장 성장 촉진요인 및 과제

위마비 치료제 시장은 성장과 발전에 영향을 미치는 다양한 촉진요인과 과제에 영향을 받습니다. 이러한 요인을 이해하는 것은 시장을 탐색하고 기회를 활용하기 위해 매우 중요합니다.

위마비 치료제 시장을 이끄는 요인은 다음과 같습니다.

• 위마비 유병률 증가: 당뇨병 및 기타 기저질환으로 인한 위마비 유병률 증가는 효과적인 치료법에 대한 수요를 촉진하고 있습니다. 인식과 진단 증가가 시장 수요 증가에 기여하고 있습니다.
• 약물 연구 발전: 새로운 치료법 및 제형 개선 등 의약품 연구 개발의 혁신으로 치료 옵션이 확대되고 있습니다. 이러한 발전은 미충족 수요를 충족시키고 효능을 향상시켜 시장 성장을 가속합니다.
• 디지털 건강 기술의 확장: 위마비 모니터링 및 관리를 위한 디지털 건강 도구의 통합은 환자 치료를 개선하고 있습니다. 이러한 기술은 실시간 증상 추적 및 치료 조정을 용이하게 하여 시장 성장을 뒷받침하고 있습니다.
• 신규 치료제에 대한 규제 지원: 규제 프로세스 간소화와 신약 승인 지원으로 새로운 치료법의 도입을 촉진하고 있습니다. 시장 접근성 개선과 신속한 승인은 위마비 치료제 시장의 성장을 가속하고 있습니다.

위마비 치료제 시장의 과제는 다음과 같습니다.

• 높은 개발 비용: 연구개발, 임상시험, 승인 획득 등 위마비 치료제의 개발 비용은 고비용이 소요될 수 있습니다. 높은 개발 비용은 신규 진입을 감소시키고 시장 역학을 변화시킬 수 있습니다.
• 제한된 환자 수: 위마비는 다른 질환에 비해 상대적으로 드물기 때문에 신약 시장 규모가 제한될 수 있습니다. 환자 수가 적기 때문에 신약 개발에 대한 투자는 기업에게 최적의 수익을 가져다주지 못할 수 있습니다.
• 치료 반응의 다양성: 위마비 치료에 대한 환자 반응의 차이는 일관된 치료 결과를 달성하는 데 어려움이 될 수 있습니다. 환자 간 치료 효과의 편차는 더 넓은 시장에서의 수용성에 영향을 미치고 환자 만족도에 영향을 미칠 수 있습니다.
• 규제적 장애물: 복잡한 규제 요건을 극복하고 새로운 치료법을 승인받는 것은 어려운 일입니다. 엄격한 규제와 긴 승인 절차는 새로운 치료법의 도입을 지연시킬 수 있습니다.

결론적으로, 이러한 촉진요인과 과제는 위마비 치료제 시장의 복잡성을 보여줍니다. 이러한 요인들을 해결하는 이해관계자들은 이 시장을 잘 헤쳐나가고 성장과 혁신의 기회를 활용할 수 있을 것으로 보입니다.

목차

제1장 주요 요약

제2장 세계의 위마비 치료제 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계 촉진요인과 과제

제3장 시장 동향과 예측 분석(2018년-2030년)

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 위마비 치료제 시장 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 위마비 치료제 시장 : 약제 클래스별
  • 소화관 운동 촉진제
  • 제토제
  • 보툴리눔톡신(보톡스) 주사
• 세계의 위마비 치료제 시장 : 질환 유형별
  • 당뇨병성 위마비
  • 특발성 위마비
  • 수술후 위마비
  • 기타
• 세계의 위마비 치료제 시장 : 유통 채널별
  • 병원
  • 약국
  • 클리닉
  • E-Commerce

제4장 지역별 시장 동향과 예측 분석(2018년-2030년)

• 세계의 위마비 치료제 시장 : 지역별
• 북미의 위마비 치료제 시장
• 유럽의 위마비 치료제 시장
• 아시아태평양의 위마비 치료제 시장
• 기타 지역의 위마비 치료제 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter의 Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 세계의 위마비 치료제 시장 성장 기회 : 약제 클래스별
  • 세계의 위마비 치료제 시장 성장 기회 : 질환 유형별
  • 세계의 위마비 치료제 시장 성장 기회 : 유통 채널별
  • 세계의 위마비 치료제 시장 성장 기회 : 지역별
• 세계 위마비 치료제 시장의 새로운 동향
• 전략적 분석
  • 신제품 개발
  • 세계의 위마비 치료제 시장 생산능력 확대
  • 세계 위마비 치료제 시장의 인수합병(M&A) 및 합작투자
  • 인증 및 라이선싱

제7장 주요 기업 개요

• Allergan
• Abbott Laboratories
• AstraZeneca
• Cadila Pharmaceuticals
• ETX Pharma
• Evoke Pharma
• GlaxoSmithKline

영문목차

Gastroparesis Drug Trends and Forecast

The future of the global gastroparesis drug market looks promising with opportunities in the diabetic gastroparesis, idiopathic gastroparesis, and post-surgical gastroparesis markets. The global gastroparesis drug market is expected to grow with a CAGR of 4.5% from 2024 to 2030. The major drivers for this market are an increase in the number of surgeries, a rising incidence rate of the diabetic population, and the launch of innovative medications designed to manage symptoms like nausea and vomiting.

• Lucintel forecasts that, within the drug class category, antiemetic agents are expected to witness the highest growth over the forecast period.
• Within the disease type category, idiopathic gastroparesis will remain the largest segment.
• In terms of regions, North America is expected to witness the highest growth over the forecast period due to a surge in the aging population, along with an increasing number of surgical procedures.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Gastroparesis Drug Market

Emerging trends in the gastroparesis drug market are reshaping its future applications and dynamics. Key trends include:

• Novel Therapeutics: New drugs targeting different mechanisms of gastroparesis are being developed. These include agents that address motility disorders more effectively and offer improved symptom management compared to current treatments.
• Extended-Release Formulations: The development of extended-release drug formulations from existing gastroparesis drugs has become a growing trend. The objective of these formulations is to provide sustained relief from symptoms by reducing the frequency of dosing, thus enhancing patient adherence.
• Combination Therapies: Combining existing drugs with new agents or therapies is becoming more common. This approach aims to enhance overall efficacy and manage symptoms more comprehensively by addressing multiple pathways involved in gastroparesis.
• Personalized Medicine: The use of genetic and biomarker information to individualize gastroparesis treatments has gained traction. Personalized approaches aim to optimize therapy based on specific patient characteristics, improving treatment outcomes.
• Digital Health Integration: With the increased focus on the future of digital health, app-based technologies and gadgets like wearables are now being used to manage symptoms of gastroparesis and ensure medication compliance. These technologies provide dynamic data and allow for more personalized treatment.

In conclusion, these emerging trends reflect significant advancements in the gastroparesis drug market, focusing on novel therapies, personalized medicine, and innovative delivery methods. These developments aim to enhance treatment efficacy and patient outcomes, driving future growth in the industry.

Recent Developments in the Gastroparesis Drug Market

Ongoing innovations and advancements in the gastroparesis drug market have been highlighted by recent developments:

• Approval of New Medications: In recent years, a number of drugs have been approved for treating gastroparesis, including specialized motility agents. These drug types use different mechanisms of action, offering alternatives for patients who do not respond positively to conventional treatments. These drugs are anticipated to greatly improve overall management and outcomes for people suffering from gastroparesis.
• Enhanced Formulations of Existing Drugs: One example is long-acting or controlled-release formulations, which reduce dosing frequency, thus improving patient compliance while enhancing symptom control efficacy. Through this approach, symptoms last longer, meaning fewer doses are necessary, making it easier for patients to follow their treatment regimens.
• Emergence of Digital Health Solutions: Technological advancements, such as mobile apps and portable gadgets, have taken gastroparesis management in a new direction. These devices allow for real-time symptom tracking and facilitate timely medication intake adjustments based on the findings from these digital health tools. Additionally, the inclusion of digital health solutions makes communication easier between patients and healthcare providers.
• Increased Focus on Combination Therapies: Some researchers are investigating how they can combine traditional drug treatments with new drugs or even non-pharmacological remedies. By doing so, multiple aspects of gastroparesis can be addressed at once, improving overall symptom control as well as patient outcomes. Consequently, clinical tests have been launched to examine whether these combinations indeed boost treatment efficacy.

In summary, these recent developments reflect a significant evolution in the gastroparesis drug market, emphasizing new medications, improved formulations, and innovative digital health solutions. These advancements are poised to enhance patient care and expand treatment options.

Strategic Growth Opportunities for Gastroparesis Drug Market

Some key strategic opportunities in this market include:

• Investment in Novel Drug Development: Creating new drugs targeted at varying gastroparesis mechanisms could result in substantial growth rates. Innovation should focus on drug design and mechanisms of action to meet unmet needs and offer better treatments.
• Expansion into Emerging Markets: There is substantial growth potential through making more products available to treat gastroparesis in emerging markets, where more people are being diagnosed, and awareness of the condition is increasing. Localizing treatments to meet regional preferences can open up wider market opportunities.
• Integration of Digital Health Technologies: Partnerships between pharmaceutical companies and mobile health firms are helping to develop combined monitoring platforms to improve outcomes for gastroparesis patients. This integration will improve adherence while providing clinicians with vital data when prescribing personalized therapies using digital platforms.
• Development of Combination Therapies: Focusing on combination therapies that integrate existing treatments with new drugs or non-pharmacological interventions can provide comprehensive management of gastroparesis. This approach can address various symptoms and improve overall treatment efficacy.
• Personalized Medicine Approaches: Investing in personalized medicine strategies, including genetic profiling and tailored treatments, can optimize therapy for individual patients. Personalized approaches can lead to better outcomes and differentiate offerings in the market.

In conclusion, these strategic growth opportunities highlight the potential for innovation and market expansion in the gastroparesis drug industry. Leveraging new technologies and approaches can drive future growth and improve patient care.

Gastroparesis Drug Market Driver and Challenges

The gastroparesis drug market is influenced by various drivers and challenges that affect its growth and development. Understanding these factors is crucial for navigating the market and capitalizing on opportunities.

The factors responsible for driving the gastroparesis drug market include:

• Increasing Prevalence of Gastroparesis: The rising prevalence of gastroparesis, driven by factors such as diabetes and other underlying conditions, is fueling demand for effective treatments. Growing awareness and diagnosis are contributing to increased market needs.
• Advancements in Drug Research: Innovations in drug research and development, including novel therapies and improved formulations, are expanding treatment options. These advancements address unmet needs and enhance efficacy, driving market growth.
• Expansion of Digital Health Technologies: The integration of digital health tools for monitoring and managing gastroparesis is improving patient care. These technologies facilitate real-time symptom tracking and treatment adjustments, supporting market growth.
• Regulatory Support for New Treatments: Streamlined regulatory processes and support for new drug approvals are facilitating the introduction of novel therapies. Improved market access and faster approvals are driving growth in the gastroparesis drug market.

Challenges in the gastroparesis drug market are:

• High Development Costs: The cost of developing new gastroparesis drugs, including research, clinical trials, and regulatory approvals, can be high. High development costs may reduce new entrants and alter market dynamics.
• Limited Patient Population: Gastroparesis is relatively rare compared to other conditions, which can limit the market size for new drugs. Investment in drug development may not provide optimal returns for companies, as the number of patients is small.
• Variability in Treatment Response: Differences in how patients respond to gastroparesis treatments can pose challenges in achieving consistent outcomes. Variations in treatment effectiveness among patients could affect its acceptance by the broader market and influence patient satisfaction.
• Regulatory Hurdles: Navigating complex regulatory requirements and gaining approvals for new treatments can be challenging. Stringent regulations and lengthy approval processes may delay the introduction of new therapies.

In conclusion, these drivers and challenges illustrate the complexities of the gastroparesis drug market. Stakeholders addressing these factors will successfully navigate this market and take advantage of growth and innovation opportunities.

List of Gastroparesis Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies gastroparesis drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the gastroparesis drug companies profiled in this report include-

• Allergan
• Abbott Laboratories
• AstraZeneca
• Cadila Pharmaceuticals
• ETX Pharma
• Evoke Pharma
• GlaxoSmithKline

Gastroparesis Drug by Segment

The study includes a forecast for the global gastroparesis drug by drug class, disease type, distribution channel, and region.

Gastroparesis Drug Market by Drug Class [Analysis by Value from 2018 to 2030]:

• Prokinetic Agents
• Antiemetic Agents
• Botulinum Toxin Injections

Gastroparesis Drug Market by Disease Type [Analysis by Value from 2018 to 2030]:

• Diabetic Gastroparesis
• Idiopathic Gastroparesis
• Post-Surgical Gastroparesis
• Others

Gastroparesis Drug Market by Distribution Channel [Analysis by Value from 2018 to 2030]:

• Hospitals
• Pharmacies
• Clinics
• e-Commerce

Gastroparesis Drug Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Gastroparesis Drug Market

Major players in the market are expanding their operations and forming strategic partnerships to strengthen their positions. The following highlights recent developments by major gastroparesis drug producers in key regions: the USA, China, India, Japan, and Germany.

• United States: The U.S. has recently seen several developments in gastroparesis drugs, including the approval of new medications and updated formulations for existing treatments. These advancements focus on improving patient adherence through the use of extended-release drug delivery systems, which help manage symptoms more effectively. Additionally, research is ongoing on the use of newer agents and combination therapies to achieve better outcomes while minimizing adverse effects.
• China: China's gastroparesis drug market is evolving with the introduction of more affordable generic versions of established drugs. There is also growing interest in developing new treatments targeting the core symptoms of gastroparesis. Research institutions are focusing on localizing drug development to address specific regional needs and improve accessibility.
• Germany: Germany has witnessed progress in treating gastroparesis, with innovations being integrated into clinical practices to improve patient access through health reforms. The country is also investing in research to gain deeper insights into the mechanisms underlying gastroparesis, including the development of targeted therapies that address patient specificity and optimize treatment effectiveness.
• India: India's gastroparesis drug market continues to grow due to efforts focused on increasing the availability of affordable treatments. Research on generics and alternative formulations has been initiated to make treatments more accessible to a wider patient population. Additionally, initiatives aimed at raising awareness about gastroparesis and its diagnosis are contributing to improved management and treatment options.
• Japan: In Japan, advancements in the gastroparesis drug market are being made through the introduction of new drugs and improvements in formulations for existing ones. This includes innovative drug delivery systems designed to optimize treatment efficacy while minimizing side effects. Japanese researchers are also exploring personalized treatments based on genetic and clinical data, aiming to optimize outcomes for patients diagnosed with gastroparesis.

Features of the Global Gastroparesis Drug Market

Market Size Estimates: Gastroparesis drug market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Gastroparesis drug market size by drug class, disease type, distribution channel, and region in terms of value ($B).

Regional Analysis: Gastroparesis drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug classes, disease types, distribution channels, and regions for the gastroparesis drug market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the gastroparesis drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the gastroparesis drug market by drug class (prokinetic agents, antiemetic agents, and botulinum toxin injections), disease type (diabetic gastroparesis, idiopathic gastroparesis, post-surgical gastroparesis, and others), distribution channel (hospitals, pharmacies, clinics, and e-commerce), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Gastroparesis Drug Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Gastroparesis Drug Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Gastroparesis Drug Market by Drug Class
  • 3.3.1: Prokinetic Agents
  • 3.3.2: Antiemetic Agents
  • 3.3.3: Botulinum Toxin Injections
• 3.4: Global Gastroparesis Drug Market by Disease Type
  • 3.4.1: Diabetic Gastroparesis
  • 3.4.2: Idiopathic Gastroparesis
  • 3.4.3: Post-surgical Gastroparesis
  • 3.4.4: Others
• 3.5: Global Gastroparesis Drug Market by Distribution Channel
  • 3.5.1: Hospitals
  • 3.5.2: Pharmacies
  • 3.5.3: Clinics
  • 3.5.4: e-commerce

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Gastroparesis Drug Market by Region
• 4.2: North American Gastroparesis Drug Market
  • 4.2.1: North American Market by Drug Class: Prokinetic Agents, Antiemetic Agents, and Botulinum Toxin Injections
  • 4.2.2: North American Market by Disease Type: Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-surgical Gastroparesis, and Others
• 4.3: European Gastroparesis Drug Market
  • 4.3.1: European Market by Drug Class: Prokinetic Agents, Antiemetic Agents, and Botulinum Toxin Injections
  • 4.3.2: European Market by Disease Type: Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-surgical Gastroparesis, and Others
• 4.4: APAC Gastroparesis Drug Market
  • 4.4.1: APAC Market by Drug Class: Prokinetic Agents, Antiemetic Agents, and Botulinum Toxin Injections
  • 4.4.2: APAC Market by Disease Type: Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-surgical Gastroparesis, and Others
• 4.5: ROW Gastroparesis Drug Market
  • 4.5.1: ROW Market by Drug Class: Prokinetic Agents, Antiemetic Agents, and Botulinum Toxin Injections
  • 4.5.2: ROW Market by Disease Type: Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-surgical Gastroparesis, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Gastroparesis Drug Market by Drug Class
  • 6.1.2: Growth Opportunities for the Global Gastroparesis Drug Market by Disease Type
  • 6.1.3: Growth Opportunities for the Global Gastroparesis Drug Market by Distribution Channel
  • 6.1.4: Growth Opportunities for the Global Gastroparesis Drug Market by Region
• 6.2: Emerging Trends in the Global Gastroparesis Drug Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Gastroparesis Drug Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Gastroparesis Drug Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Allergan
• 7.2: Abbott Laboratories
• 7.3: AstraZeneca
• 7.4: Cadila Pharmaceuticals
• 7.5: ETX Pharma
• 7.6: Evoke Pharma
• 7.7: GlaxoSmithKline